And if the best evidence available cannot exclude serious harm from the treatment?
-
-
I agree reasonably strongly for drugs early in patent, but for repurposed drugs harder to apply.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Remdesivir is a perfect example of a big problem in pharma. Small subgroups who disproportionately benefit from a drug are of no interest to you if you are selling a drug. They'd prefer a modest effect size just big enough to keep being used for as big a customer base.
-
It's clear the mortality benefit exists in early, low flow o2 requirement state
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.